• Record full year revenue of $10.9million, up 10.8% on prior year.
• Underlying Profit is in line with expectations
• IPO costs(one-off) and non-cash share based payments expenses impact FY2018 profit
The Company has pleasure in announcing its operating results for the year ended 30 June 2018.
Star Combo Pharma Ltd (“The Company or Star Combo”) derives its revenue through the manufacture and sale of vitamins and dietary supplements.
For further information please download PDF attached:
Download this document